Related Experiment Video

Updated: Aug 9, 2026

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
11:44

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

ARF-BP1 as a potential therapeutic target

D Chen1, C L Brooks, W Gu

  • 1Institute for Cancer Genetics, Department of Pathology, College of Physicians and Surgeons, Columbia University, 1150 St Nicholas Ave, New York, NY 10032, USA.

British Journal of Cancer
|April 28, 2006
PubMed

Insights

ARF-BP1, an E3 ubiquitin ligase, regulates p53 stability and apoptosis. Inhibiting ARF-BP1 offers a promising new cancer therapy strategy, effective even in p53-deficient tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • ARF-BP1 (also known as Mule, UREB1, E3(histone), LASU1, and HectH9) is a recently identified HECT domain-containing E3 ubiquitin ligase.
  • ARF-BP1 interacts with tumor suppressors ARF and p53.
  • The E3 ubiquitin ligase activity of ARF-BP1 is regulated by ARF.

Purpose of the Study:

  • To review the role of ARF-BP1 in cancer.
  • To explore ARF-BP1 as a potential therapeutic target.

Main Methods:

  • Literature review of ARF-BP1 function.
  • Analysis of ARF-BP1 interactions with ARF and p53.
  • Investigation of ARF-BP1's impact on p53 stability and apoptosis.

Main Results:

  • ARF inhibits the ubiquitin ligase activity of ARF-BP1.
  • Inactivation of ARF-BP1 leads to p53 stabilization and apoptosis induction.
  • ARF-BP1 inactivation suppresses tumor growth in p53-null and mutant p53 cancer cells.

Conclusions:

  • ARF-BP1 is a critical regulator of p53.
  • Targeting ARF-BP1 represents a novel therapeutic strategy for various cancers, irrespective of p53 status.

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...